Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

Rosenstock, Julio; Hansen, Melissa Voigt; Goldenberg, Ronald

doi:10.1056/nejmoa2022474

Cited by 170 publications

(188 citation statements)

References 16 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…Once-weekly insulin An investigational once-weekly formulation of an acylated degradation-resistant insulin, at present provisionally designated insulin icodec, was assessed in a 26 week Phase II trial in people with type 2 diabetes. Compared with once-daily insulin glargine U100, starting at a dose of 70 U and up-titrated weekly to a mean dose of 241 U/week, insulin icodec exhibited a comparable safety and efficacy profile when added to a background regimen of metformin with or without a dipeptidyl peptidase-4 inhibitor [2]. Rates of minor (level 1) hypoglycaemia and the relative reduction of HbA 1c was numerically greater with insulin icodec than insulin glargine U100.…”

Section: New Methods For Delivery Of Insulinmentioning

confidence: 95%

Transforming type 1 diabetes: the next wave of innovation

Drucker

2021

Diabetologia

View full text Add to dashboard Cite

The discovery of insulin in 1921 enabled pharmaceutical production of animal insulins for the treatment of people with type 1 diabetes by 1922. The last several decades have witnessed enormous scientific progress in the therapy of type 1 diabetes, yet some developments have been incremental, and insulin is not a cure. Herein, I highlight key scientific advances potentially poised to improve the quality of life and treatment outcomes in type 1 diabetes. These innovations range from newer insulin analogues to the development of smart insulins, oral and weekly insulins, glucose sensors and closed-loop insulin-delivery devices, as well as strategies for durable human beta cell replacement coupled with selective immune manipulation to preserve beta cell function. Finally, progress in the prediction and prevention of type 1 diabetes highlights the ongoing challenges and potential for altering the natural history of the disease or eliminating type 1 diabetes altogether.

show abstract

Section: New Methods For Delivery Of Insulinmentioning

confidence: 95%

Transforming type 1 diabetes: the next wave of innovation

Drucker

2021

Diabetologia

View full text Add to dashboard Cite

show abstract

“…Still, major innovations are to be expected in the manufacturing of insulins in the following years. In the short term, ultra-long-acting, once-weekly insulins will be available [43]. Most patients applaud this evolution, while most clinicians are sceptical, in particular because of fear of hypoglycaemia.…”

Section: The Future For Insulin and Hypoglycaemiamentioning

confidence: 99%

Minimising hypoglycaemia in the real world: the challenge of insulin

Mathieu

2021

Diabetologia

View full text Add to dashboard Cite

Insulin therapy has been a life saver for people with type 1 diabetes and has been an essential tool in the therapy of people with type 2 diabetes, but the risk for hypoglycaemia has been a major hurdle to achieving good glycaemic control for most. Insulin analogues, the availability of novel technologies for the administration of insulin, like insulin pumps, and, in particular, tools to measure glucose levels, evolving from capillary measurements to continuous glucose monitoring, have revolutionised the way in which people living with diabetes use insulin. Novel insulin concepts, like once-weekly or oral insulin administration, will have to demonstrate safety on the side of hypoglycaemia before they will be able to move into the clinic.

show abstract

“…Insulin icodec is a basal insulin analogue administered onceweekly with a time to maximum concentration of 16 hours and a half-life of approximately 1 week, with a profile suitable for once-weekly injection [27]. The findings of a phase 2 clinical trial designed to investigate the efficacy and safety of onceweekly insulin icodec as compared with once-daily insulin glargine U100 in T2DM patients without a previous history of insulin injection in whom T2DM was inadequately controlled with metformin with or without a dipeptidyl peptidase-4 inhibitor.…”

Section: Once-weekly Insulin For T2dm Without Previous Insulin Treatmentmentioning

confidence: 99%

Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020

2021

View full text Add to dashboard Cite

Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few to numerous, enabling clinicians to personalize diabetes care and treatment. Thanks to rapid growth in the field of science and medical engineering, newer treatment options are coming to the market with various advantages and disadvantages to be aware of. Therefore, clinicians should rapidly adopt new trends based on guidelines and data from many clinical trials in the field of diabetes. In the treatment of dyslipidemia, trends and guidelines are changing every year, and novel therapies are being developed. In this review, we would like to summarize the major achievements in clinical medicine in 2020 in the field of diabetes mellitus and dyslipidemia.

show abstract

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

Cited by 170 publications

References 16 publications

Transforming type 1 diabetes: the next wave of innovation

Transforming type 1 diabetes: the next wave of innovation

Minimising hypoglycaemia in the real world: the challenge of insulin

Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020

Contact Info

Product

Resources

About